The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical device company PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development
  • Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations
  • He will focus on quickly growing a research and development team to capture and commercialise the many business developments and new product opportunities
  • On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share

PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development.

Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations.

Previously, he has worked as product development manager, operations director, research and development director and Chief Technology Officer at SDI, a medical devices company that specialises in manufacturing dental materials.

Joshua will focus on quickly growing a research and development team to
capture and commercialise the many business developments and new product opportunities.

His role is to lead the innovation strategy and research and development activities and to develop the future product portfolio for PolyNovo.

“This is a very exciting and significant appointment that will spearhead the
building of a world-class research and development team befitting the company’s market capitalisation,” Chairman David Williams said.

Managing Director Paul Brennan says the company will continue to invest in the expansion of its research and development team.

“Joshua will be recruiting additional scientists to bolster the team and accelerate our pipeline of new products,” he added.

On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share.

PNV by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…